BioInvent International
11.12.2021 23:46:53 CET | ACCESS Newswire | Press release
- Objective response rate (ORR) 67% and disease control rate (DCR) 78% in Follicular lymphoma
- Complete responses lasting beyond 18, 24 and 36 months
LUND, SWEDEN / ACCESSWIRE / December 11, 2021 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces updated positive interim top-line data from its novel anti-FcyRIIB antibody BI-1206 that show increased response levels and sustained complete responses. The data represent the status - to early November 2021 - of the company's Phase 1/2a clinical trial of BI-1206 in combination with rituximab (anti-CD20 monoclonal antibody) treating patients with indolent relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). They are published today in a poster at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH 2021).
The ASH 2021 poster shows that BI-1206 in combination with rituximab provided an objective response rate (ORR) of 54%, with three complete responses and four partial responses in 13 patients evaluated for therapeutic benefit for the three indications (Mantle cell lymphoma, Marginal zone lymphoma and Follicular lymphoma) enrolled in the clinical study. The treatment stabilized disease in one additional patient, giving a disease control rate of 62% (8 out of 13 patients).
When considered alone, the response rate for Follicular lymphoma is particularly impressive: of nine evaluable patients, three developed a CR, three developed a PR and one patient had SD at the cut-off date, giving a 67% ORR and 78% DCR. Previous rituximab treatments without BI-1206 had failed in these patients, prior to participation in the trial all patients had relapsed on earlier lines of rituximab-containing treatments.
All complete responses have been sustained for extended periods, with the longest complete response enduring beyond 36 months. In two additional patients, complete responses have lasted beyond 12 and 24 months after end of treatment.
"The current data are highly encouraging and already show the benefit of BI-1206 in rescuing rituximab treatment in advanced NHL. Without BI-1206, rituximab did not work well in these patients. Based on our deep understanding of the immune mechanisms at play, these data indicate that BI-1206 not only restores the anti-tumor response but does it safely and in a prolonged manner in many patients, notably in Follicular lymphoma. Adjusting the dosing regimen of BI-1206 could lead to yet further improvements. We look forward to discussing all these aspects with investors during our forthcoming KOL call on December 17," said Martin Welschof, PhD, CEO of BioInvent.
BioInvent will host a key opinion leader (KOL) webinar on BI-1206 featuring Michael Wang, M.D., from the MD Anderson Cancer Center, who will discuss the current NHL treatment landscape and unmet medical needs. Senior management will discuss the data presented at ASH 2021 and first data from the Phase 1/2a study of BI-1206 in combination with pembrolizumab for the treatment of solid tumors. The webinar will take place on Friday, December 17, 2021, at 1:00 pm ET/7:00 pm CET.
To register for the webinar, please click here .
BI-1206 is BioInvent's lead drug candidate and is currently being investigated in two Phase 1/2 trials. One is evaluating the BI-1206 combination with rituximab for the treatment of non-Hodgkin's lymphoma; and the other evaluates BI-1206 in combination with anti-PD1 therapy Keytruda® (pembrolizumab) in solid tumors. BI-1206 has also received approval to start clinical trials in China.
Since October 2020, BioInvent has a licensing agreement in place with CASI Pharmaceuticals for China, including Hong Kong, Macau, and Taiwan. Under the terms of the agreement, BioInvent and CASI will develop BI-1206 in both hematological and solid cancers, with CASI responsible for commercialization in China and associated markets.
ASH 2021 will take place on December 11-14, 2021, at the Georgia World Congress Center - Atlanta, GA, and virtually. BioInvent's poster is entitled "Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to FcyRIIB, in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or is Refractory to Rituximab". The poster is presented today December 11 at 5.30 pm ET (11:30 pm CET).
About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively and a fifth program just initiating clinical development. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com .
For further information, please contact:
Cecilia Hofvander
Senior Director Investor Relations
+46 (0)46 286 85 50
cecilia.hofvander@bioinvent.com
BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com
Disclaimer - BioInvent
The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.
This information is information that BioInvent International is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-12-11 23:30 CET.
Attachments
SOURCE: BioInvent International
View source version on accesswire.com:
https://www.accesswire.com/677141/BioInvents-Latest-NHL-Data-at-ASH-Show-Increased-and-Sustained-Responses-to-BI-1206-in-Relapsed-Patients
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
MicroVision and LAKE FUSION Technologies Sign Multi-Year Strategic Partnership Agreement for IRIS(TM) Lidar Sensors5.11.2026 15:20:00 CET | Press release
ORLANDO, FL AND MARKDORF, GERMANY / ACCESS Newswire / November 5, 2026 / MicroVision, Inc. (NASDAQ:MVIS), a leader in advanced perception solutions for industrial, security and defense, intelligent infrastructure, and automotive mobility, today announced a multi-year strategic partnership agreement with LAKE FUSION Technologies (LFT), a German developer of advanced sensor fusion and situational awareness systems. Under the agreement, LFT has committed to purchasing MicroVision IRIS™ long-range lidar sensors throughout 2027 and into 2028 for integration into its Awareness Systems (AS-1), designed to enhance safety and obstacle detection for civil and military helicopter operations. The multi-year agreement marks another significant commercial milestone following the companies' June 2026 announcement to expedite the integration of IRIS lidar technology and accelerate the deployment of advanced situational awareness solutions. With testing and evaluation progressing into a formal strategi
Chervon Names Doug Palmer Vice President of Finance - Canada5.11.2026 15:00:00 CET | Press release
TORONTO, ON / ACCESS Newswire / November 5, 2026 / Effective November 9, 2026, Chervon names Doug Palmer Vice President of Finance - Canada, reporting to Neil Harrison, Vice President and Managing Director of Chervon Canada. He will also have a dotted-line reporting relationship to Ryan Wang, Chief Financial Officer, Chervon NA. Palmer brings to Chervon an exceptional 20-year career of increasingly responsible positions in Canadian financial management. During his 18-year career at J.M. Smucker, he held financial management positions as Analyst, Senior Manager, Director, and Senior Director, responsible for all elements of financial control and FP&A. Most recently, he served as Vice President of Finance at the Crump Group. "We have identified Canada as a strategic priority for Chervon with massive growth potential," said Joe Galli, Chervon CEO. "We are building the best leadership team in the Power Tool and OPE industry in Canada. Doug Palmer is an outstanding addition to this high-per
New EuroFinance Study, Sponsored by TIS, Puts Treasury at the Center of Cybersecurity5.11.2026 15:00:00 CET | Press release
BERLIN, DE / ACCESS Newswire / November 5, 2026 / New Deep Dive research, Cyber Risk Management: No Longer Just an IT Problem, finds that cyber risk is increasingly disrupting payments, liquidity management, and business continuity. Sponsored by TIS, a global leader in payments and cash management technology, the new report extracts insights from treasury and cybersecurity professionals across housing, commodities, manufacturing, consumer goods, and telecommunications who agree that cybersecurity is a growing treasury and liquidity risk. Why Treasury Is at the Center of Cyber Risk The ongoing digitization of the treasury ecosystem through APIs, cloud platforms, and automation has increased the speed and efficiency of treasury operations. While treasury teams are moving faster, their exposure to sophisticated cyber threats, including deepfake videos, fraudulent invoices, and manipulating approvals through compromised digital channels, has expanded in proportion. These threats most frequ
Polaris Renewable Energy Announces Q3 2026 Results5.11.2026 14:25:00 CET | Press release
TORONTO, ON / ACCESS Newswire / November 5, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris Renewable Energy" or the "Company"), is pleased to report its financial and operating results for the three and nine months ended September 30, 2026. This earnings release should be read in conjunction with the Company's consolidated financial statements and management's discussion and analysis, which are available on the Company's website at www.PolarisREI.com and have been posted on SEDAR+ at www.sedarplus.ca. The dollar figures below are denominated in US Dollars unless noted otherwise. HIGHLIGHTSThird quarter consolidated energy production totaled 175,791 MWh, a 3% decrease from 181,235 MWh in the same quarter last year. The decrease primarily reflected lower generation in the Dominican Republic and the Company's hydroelectric facilities in Peru and Ecuador, partially offset by stronger wind generation in Puerto Rico.The Company generated $19,005 in revenue from energy sales for the
Polaris Renewable Energy Declares Quarterly Dividend5.11.2026 14:20:00 CET | Press release
TORONTO, ON / ACCESS Newswire / November 5, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris Renewable Energy" or the "Company"), is pleased to announce that its board of directors has declared a quarterly dividend of US$0.15 per common share outstanding. This dividend will be paid on November 20th, 2026, to shareholders of record at the close of business on November 12th, 2026. The dividend is an "eligible dividend" as designated for Canadian federal, provincial, and territorial income tax purposes. The board of directors of Polaris Renewable Energy remains committed to paying a quarterly dividend and will evaluate further dividend increases, as appropriate, going forward. About Polaris Renewable Energy Inc. Polaris Renewable Energy Inc. is a Canadian publicly traded company engaged in the acquisition, development, and operation of renewable energy projects in Latin America and the Caribbean. We are a high-performing and financially sound contributor to the energy transition.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom